CareX SA, a France-based biopharmaceutical company, specializes in developing novel therapies for metabolic syndrome, a group of related disorders that affect the body's metabolism and increase the risk of conditions like type 2 diabetes, heart diseases, and strokes. The company uses advanced techniques such as X-ray crystallography, high-throughput screening, and medicinal chemistry to create small molecule drug candidates that target insulin resistance syndrome. These therapeutics have potential applications in treating obesity, type II diabetes, dyslipidemia, and cardiovascular disease.